EP2827852A4 - Formulation à libération prolongée pour réduire la fréquence de miction et son procédé d'utilisation - Google Patents

Formulation à libération prolongée pour réduire la fréquence de miction et son procédé d'utilisation

Info

Publication number
EP2827852A4
EP2827852A4 EP13763764.1A EP13763764A EP2827852A4 EP 2827852 A4 EP2827852 A4 EP 2827852A4 EP 13763764 A EP13763764 A EP 13763764A EP 2827852 A4 EP2827852 A4 EP 2827852A4
Authority
EP
European Patent Office
Prior art keywords
urination
extended
frequency
reducing
release formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13763764.1A
Other languages
German (de)
English (en)
Other versions
EP2827852A1 (fr
Inventor
David A Dill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellesley Pharmaceuticals LLC
Original Assignee
Wellesley Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed by Wellesley Pharmaceuticals LLC filed Critical Wellesley Pharmaceuticals LLC
Publication of EP2827852A1 publication Critical patent/EP2827852A1/fr
Publication of EP2827852A4 publication Critical patent/EP2827852A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP13763764.1A 2012-03-19 2013-03-13 Formulation à libération prolongée pour réduire la fréquence de miction et son procédé d'utilisation Withdrawn EP2827852A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
PCT/US2013/030901 WO2013142197A1 (fr) 2012-03-19 2013-03-13 Formulation à libération prolongée pour réduire la fréquence de miction et son procédé d'utilisation

Publications (2)

Publication Number Publication Date
EP2827852A1 EP2827852A1 (fr) 2015-01-28
EP2827852A4 true EP2827852A4 (fr) 2016-03-02

Family

ID=49223209

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13763764.1A Withdrawn EP2827852A4 (fr) 2012-03-19 2013-03-13 Formulation à libération prolongée pour réduire la fréquence de miction et son procédé d'utilisation
EP13763665.0A Withdrawn EP2827851A4 (fr) 2012-03-19 2013-03-14 Formulation à libération prolongée pour réduire la fréquence de la miction et procédé d'utilisation de celle-ci

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP13763665.0A Withdrawn EP2827851A4 (fr) 2012-03-19 2013-03-14 Formulation à libération prolongée pour réduire la fréquence de la miction et procédé d'utilisation de celle-ci

Country Status (15)

Country Link
EP (2) EP2827852A4 (fr)
JP (5) JP2015510928A (fr)
KR (4) KR20140134333A (fr)
CN (4) CN107157991A (fr)
AU (4) AU2013235518B2 (fr)
BR (2) BR112014020271A8 (fr)
CA (2) CA2866853A1 (fr)
HK (3) HK1251469A1 (fr)
MX (3) MX2014011128A (fr)
MY (2) MY174090A (fr)
NZ (6) NZ714288A (fr)
RU (3) RU2669565C2 (fr)
SG (2) SG11201500408VA (fr)
WO (2) WO2013142197A1 (fr)
ZA (2) ZA201405862B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
MX2016001030A (es) 2013-07-23 2016-10-07 Allergan Inc Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
JP2017516832A (ja) * 2014-06-06 2017-06-22 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための医薬製剤およびその使用の方法
KR101809908B1 (ko) * 2014-07-21 2018-01-25 주식회사 종근당 5-알파환원효소억제제를 포함하는 조성물
ES2923438T3 (es) * 2014-11-20 2022-09-27 Serenity Pharmaceuticals Llc Composiciones que comprenden bajas dosis de desmopresina en combinación con un antagonista del receptor alfaadrenérgico
EP3355864A4 (fr) * 2015-09-30 2019-05-22 Wellesley Pharmaceuticals, LLC Composition pour réduire la fréquence de la miction, procédé de fabrication et d'utilisation de celle-ci
WO2017058436A1 (fr) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition pour réduire la fréquence de la miction, procédé de fabrication et d'utilisation de celle-ci
CN105238124B (zh) * 2015-11-16 2018-02-09 太仓东能环保设备有限公司 一种抗菌腻子粉
JP6294924B2 (ja) 2016-09-05 2018-03-14 株式会社Ｓｕｂａｒｕ 車両の走行制御装置

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1053752A1 (fr) * 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations a liberation controlee
WO2001019350A1 (fr) * 1999-09-14 2001-03-22 Copley Pharmaceutical Inc. Preparation a liberation controlee destinee a l'administration d'un derive naphtalene anti-inflammatoire
WO2003070233A1 (fr) * 2002-02-19 2003-08-28 Pharmacia Corporation Utilisation d'inhibiteurs de la cyclooxygenase et d'agents anti-muscariniques destinee au traitement de l'incontinence
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
US20040198822A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmacueticals, Inc. Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
EP1627876A1 (fr) * 2004-08-20 2006-02-22 Ferring B.V. Composés hétérocycliques condensés et leur usage et leur utilisation comme anti-diurétiques
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2010138441A1 (fr) * 2009-05-28 2010-12-02 Aptapharma, Inc. Comprimés oraux multicouches contenant un médicament anti-inflammatoire non stéroïdien et/ou de l'acétaminophène
WO2011107755A2 (fr) * 2010-03-05 2011-09-09 University Of Strathclyde Administration immédiate / retardée de médicament
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
IL165370A0 (en) * 2002-06-07 2006-01-15 Astellas Pharma Inc Therapeutic agent for overactive bladder
CN1758904A (zh) * 2003-03-21 2006-04-12 麦克内尔-Ppc股份有限公司 非甾体抗炎药物的给药方案
EP2400300A1 (fr) * 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Procédé de sélection d'agents préventifs/remèdes pour l'incontinence de stress
TW200716140A (en) * 2005-06-17 2007-05-01 Dynamis Therapeutics Inc Treatment of inflammatory conditions
ATE506059T1 (de) * 2005-09-02 2011-05-15 Theravida Inc Therapie zur behandlung der überaktiven blase
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1053752A1 (fr) * 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations a liberation controlee
WO2001019350A1 (fr) * 1999-09-14 2001-03-22 Copley Pharmaceutical Inc. Preparation a liberation controlee destinee a l'administration d'un derive naphtalene anti-inflammatoire
WO2003070233A1 (fr) * 2002-02-19 2003-08-28 Pharmacia Corporation Utilisation d'inhibiteurs de la cyclooxygenase et d'agents anti-muscariniques destinee au traitement de l'incontinence
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
US20040198822A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmacueticals, Inc. Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
EP1627876A1 (fr) * 2004-08-20 2006-02-22 Ferring B.V. Composés hétérocycliques condensés et leur usage et leur utilisation comme anti-diurétiques
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2010138441A1 (fr) * 2009-05-28 2010-12-02 Aptapharma, Inc. Comprimés oraux multicouches contenant un médicament anti-inflammatoire non stéroïdien et/ou de l'acétaminophène
WO2011107755A2 (fr) * 2010-03-05 2011-09-09 University Of Strathclyde Administration immédiate / retardée de médicament
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ADDLA S K ET AL: "Diclofenac for Treatment of Nocturia Caused by Nocturnal Polyuria: A Prospective, Randomised, Double-Blind, Placebo-Controlled Crossover Study", EUROPEAN UROLOGY, ELSEVIER BV, NL, vol. 49, no. 4, 1 April 2006 (2006-04-01), pages 720 - 726, XP027881854, ISSN: 0302-2838, [retrieved on 20060401] *
KOUSEI MIWA, YOSHINORI NISHINO, MINA KIKUCHI, TAKAKO MASUE, YOJI MORIYAMA, TAKASHI DEGUCHI: "Efficacy of combination therapy with tamsulosin and zolpidem on nocturia in patients with benign prostatic hyperplasia", CENTRAL EUROPEAN JOURNAL OF UROLOGY, vol. 4, 30 April 2011 (2011-04-30), pages 232 - 235, XP002743173, ISSN: 2080-4806 *
MATTHIESEN ET AL: "Nocturnal Polyuria and Natriuresis in Male Patients with Nocturia and Lower Urinary Tract Symptoms", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 156, no. 4, 1 October 1996 (1996-10-01), pages 1292 - 1299, XP005573755, ISSN: 0022-5347, DOI: 10.1016/S0022-5347(01)65572-1 *
PINNA C ET AL: "Altered neurogenic and mechanical responses to acetylcholine, ATP and substance P in detrusor from rat with outlet obstruction", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 79, no. 13, 22 August 2006 (2006-08-22), pages 1301 - 1306, XP028051173, ISSN: 0024-3205, [retrieved on 20060822], DOI: 10.1016/J.LFS.2006.03.035 *
See also references of WO2013142197A1 *
WEIN A J ET AL: "Overactive Bladder: A Better Understanding of Pathophysiology, Diagnosis and Management", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 175, no. 3, 1 March 2006 (2006-03-01), pages S5 - S10, XP024989968, ISSN: 0022-5347, [retrieved on 20060301], DOI: 10.1016/S0022-5347(05)00313-7 *
WEISS ET AL: "NOCTURIA", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 163, no. 1, 1 January 2000 (2000-01-01), pages 5 - 12, XP005556162, ISSN: 0022-5347, DOI: 10.1016/S0022-5347(05)67961-X *
YOKOYAMA, O., MATSUTA, Y., YANAI-INAMURA, H., WATANABE, M., OHTAKE, A., SUZUKI, M. AND SASAMATA, M.: "Zolpidem increases bladder capacity and decreases urine excretion in rats", NEUROUROLOGY AND URODYNAMICS, vol. 29, no. 4, 30 April 2010 (2010-04-30), pages 587 - 591, XP002743174, DOI: 10.1002/nau.20797 *

Also Published As

Publication number Publication date
AU2013235518A1 (en) 2014-09-25
RU2016133305A3 (fr) 2018-12-10
JP2015510936A (ja) 2015-04-13
MX2014011129A (es) 2015-08-10
AU2013235507A1 (en) 2014-08-21
AU2017203246B2 (en) 2018-10-18
MY174090A (en) 2020-03-09
AU2013235518A2 (en) 2014-10-09
CN104302284A (zh) 2015-01-21
JP2015510928A (ja) 2015-04-13
RU2014142066A (ru) 2016-05-10
EP2827852A1 (fr) 2015-01-28
WO2013142274A1 (fr) 2013-09-26
MX2019008817A (es) 2019-09-26
CN107157991A (zh) 2017-09-15
NZ630471A (en) 2016-04-29
KR20140134284A (ko) 2014-11-21
BR112014020113A2 (fr) 2017-06-20
RU2599017C2 (ru) 2016-10-10
CN107789626A (zh) 2018-03-13
HK1243921A1 (zh) 2018-07-27
NZ714288A (en) 2016-12-23
CA2866853A1 (fr) 2013-07-26
JP2018024693A (ja) 2018-02-15
NZ714662A (en) 2016-08-26
AU2017203139B2 (en) 2018-07-19
ZA201406146B (en) 2016-08-31
MY175764A (en) 2020-07-08
SG11201500409SA (en) 2015-03-30
RU2016133305A (ru) 2018-12-10
MX2014011128A (es) 2015-08-10
JP2016172752A (ja) 2016-09-29
AU2017203139A1 (en) 2017-06-01
BR112014020113A8 (pt) 2017-07-11
EP2827851A4 (fr) 2015-10-14
KR20170015537A (ko) 2017-02-08
NZ628079A (en) 2016-05-27
AU2017203246A1 (en) 2017-06-08
WO2013142197A1 (fr) 2013-09-26
BR112014020271A2 (fr) 2017-06-20
NZ718163A (en) 2017-09-29
HK1251469A1 (zh) 2019-02-01
HK1204553A1 (en) 2015-11-27
KR20140134333A (ko) 2014-11-21
JP2018138602A (ja) 2018-09-06
RU2669565C2 (ru) 2018-10-12
CA2866755A1 (fr) 2013-09-26
KR20190003840A (ko) 2019-01-09
NZ712594A (en) 2016-09-30
AU2013235518B2 (en) 2017-03-02
EP2827851A1 (fr) 2015-01-28
RU2014142025A (ru) 2016-05-10
AU2013235507B2 (en) 2017-03-23
BR112014020271A8 (pt) 2017-07-11
SG11201500408VA (en) 2015-03-30
CN104321056A (zh) 2015-01-28
ZA201405862B (en) 2016-08-31

Similar Documents

Publication Publication Date Title
IL274404A (en) Body expandable device and method for use
IL261768B (en) Devices and methods for tissue treatment
HK1243921A1 (zh) 用於緩解尿頻的延長釋放製劑及其使用方法
IL232715A0 (en) The delayed-release composition for reducing the frequency of urination and a method for using it
HK1200690A1 (en) Expandable body device and method of use
ZA201403762B (en) Delayed-release formulation for reducing the frequency of urination and method of use thereof
ME03469B (fr) Dérivés monométhyle triterpénoïdes en c4 et leurs procédés d'utilisation
EP2709562A4 (fr) Dispositifs de maintien de tissus et procédés d'utilisation
EP2613735A4 (fr) Dispositifs et méthodes utilisés pour le traitement d'anomalies vasculaires
EP2825242A4 (fr) Dispositifs et méthodes pour le traitement d'anomalies vasculaires
EP2790709A4 (fr) Agents hémostatiques et procédés d'utilisation
EP2938289A4 (fr) Dispositifs et procédés pour le traitement de défauts vasculaires
ZA201408055B (en) Compositions and methods for the treatment of local pain
IL261232A (en) A pharmaceutical formulation for reducing urinary frequency and a method for its use
HK1249438A1 (zh) 用於緩解尿頻的緩釋製劑及其使用方法
HK1203395A1 (en) Implantable devices and methods for the evaluation of active agent
HK1248549A1 (zh) 用於緩解尿頻的延長釋放製劑及其使用方法
HK1203159A1 (en) Prophylactic agent and or therapeutic agent for stress urinary incontinence
AP3759A (en) Method for preparing phenyloxymethyl-nitro-imidazole derivatives and use of the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140812

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/616 20060101ALI20150818BHEP

Ipc: A61K 31/167 20060101ALI20150818BHEP

Ipc: A61K 31/12 20060101AFI20150818BHEP

Ipc: A61K 31/192 20060101ALI20150818BHEP

Ipc: A61P 7/12 20060101ALI20150818BHEP

Ipc: A61K 31/405 20060101ALI20150818BHEP

Ipc: A61K 45/06 20060101ALI20150818BHEP

Ipc: A61K 9/00 20060101ALI20150818BHEP

Ipc: A61P 13/10 20060101ALI20150818BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160202

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 7/12 20060101ALI20160127BHEP

Ipc: A61K 31/616 20060101ALI20160127BHEP

Ipc: A61K 31/12 20060101AFI20160127BHEP

Ipc: A61K 31/405 20060101ALI20160127BHEP

Ipc: A61K 31/167 20060101ALI20160127BHEP

Ipc: A61K 9/00 20060101ALI20160127BHEP

Ipc: A61K 31/192 20060101ALI20160127BHEP

Ipc: A61P 13/10 20060101ALI20160127BHEP

Ipc: A61K 45/06 20060101ALI20160127BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20181206

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210226